Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Thursday, August 14, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co.

Finally, add PepsiCo (NASDAQ: PEP) to your list of S&P 500 dividend stocks to buy and hold forever while you can plug into ...

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...

Operator: Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...

Pyxis Oncology anticipates having preliminary data from the Phase 1/2 combination study of MICVO in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in R/M HNSCC and other ...

Reports Q2 revenue $2.8M vs. $0 last year. “We are invigorated by the progress we’re making, particularly in our ongoing clinical trials, where ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter ...